<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>53</patient-age><report-id>US-VERTEX PHARMACEUTICALS INC.-2013-000837</report-id><gender>unknown</gender><reactions><reaction>dry skin</reaction><reaction>RASH AND ITCHING ON THIGHS AND CALVES</reaction><reaction>anal itching</reaction><reaction>anal burning</reaction><reaction>facial itching</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>VX-950 (Telaprevir)</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>RIBAVIRIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PEGASYS</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Hepatitis C</indication></indications><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>uspader</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>30759_111</messagenumb>
		<messagesenderidentifier>VERTEXP2</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151832</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>US-VERTEX PHARMACEUTICALS INC.-2013-000837</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-16</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-21</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>2</fulfillexpeditecriteria>
		<companynumb>US-VERTEX PHARMACEUTICALS INC.-2013-000837</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
			<studyname>Solicited Program</studyname>
			<sponsorstudynumb>Solicited - Accredo</sponsorstudynumb>
			<observestudytype>3</observestudytype>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>VERTEXP2</senderorganization>
			<senderdepartment>Global Patient Safety</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>Sean</sendergivename>
			<senderfamilyname>Darcy</senderfamilyname>
			<senderstreetaddress>130 Waverly Street</senderstreetaddress>
			<sendercity>Cambridge</sendercity>
			<senderstate>MA</senderstate>
			<senderpostcode>02139</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<senderemailaddress>VRTXGPS_SubmissionTracking@vrtx.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>Office of Surveillence and Epidemiology</receiverdepartment>
			<receivertitle>Mr.</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receiverfax>3019183134</receiverfax>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>M-B</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19590830</patientbirthdate>
			<patientweight>69</patientweight>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hepatitis C</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>dry skin</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Dry skin</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dry skin</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20130115</reactionstartdate>
				<reactionfirsttime>4</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>RASH AND ITCHING ON THIGHS AND CALVES</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Rash pruritic</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Rash pruritic</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201301</reactionstartdate>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>anal itching</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Perianal itching</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Anal pruritus</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20130115</reactionstartdate>
				<reactionfirsttime>4</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>anal burning</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Burning anal</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Anorectal discomfort</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20130115</reactionstartdate>
				<reactionfirsttime>4</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>facial itching</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Itching</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pruritus</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201301</reactionstartdate>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>VX-950 (Telaprevir)</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugbatchnumb>244048</drugbatchnumb>
				<drugauthorizationnumb>201917</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Vertex Pharmaceuticals Inc.</drugauthorizationholder>
				<drugstructuredosagenumb>750</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>750 mg, tid</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2013-01-11</drugstartdate>
				<drugstartperiod>4</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug code="4">Dose not changed</actiondrug>
				<drugadditional code="ExpDT=30-NOV-2013"/>
				<activesubstance>
					<activesubstancename>VX-950</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anal pruritus</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anal pruritus</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anorectal discomfort</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anorectal discomfort</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dry skin</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dry skin</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pruritus</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pruritus</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Rash pruritic</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Rash pruritic</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>RIBAVIRIN</medicinalproduct>
				<drugstructuredosagenumb>600</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>600 mg, bid</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2013-01-11</drugstartdate>
				<drugstartperiod>4</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>RIBAVIRIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>PEGASYS</medicinalproduct>
				<drugstructuredosagenumb>180</drugstructuredosagenumb>
				<drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
				<drugdosagetext>180 습g, weekly</drugdosagetext>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2013-01-11</drugstartdate>
				<drugstartperiod>4</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>PEGINTERFERON ALFA-2A</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>A solicited non serious report of <Semaphore x="1864942" class="Disease or Finding" value="Dry Skin" score="1.00" ID="C74592"><Semaphore x="1864942" class="Disease or Finding" value="Dry Skin" score="1.00" ID="C74592">DRY </Semaphore>SKIN</Semaphore>, <Semaphore x="2746240" class="MedDRA LLT" value="Anorectal discomfort" score="1.00" ID="10068286"><Semaphore x="1534023" class="AnatomicStructure" value="Anus" score="1.00" ID="C43362">ANAL </Semaphore><Semaphore x="2060292" class="Disease or Finding" value="Integumentary System Signs and Symptoms" score="0.58" ID="C5036">ITCHING</Semaphore>, <Semaphore x="2746240" class="MedDRA LLT" value="Anorectal discomfort" score="1.00" ID="10068286"><Semaphore x="1534023" class="AnatomicStructure" value="Anus" score="1.00" ID="C43362">ANAL </Semaphore>BURNING</Semaphore></Semaphore>, <Semaphore x="1918283" class="AnatomicStructure" value="Face" score="1.00" ID="C13071">FACIAL </Semaphore><Semaphore x="2060292" class="Disease or Finding" value="Integumentary System Signs and Symptoms" score="0.58" ID="C5036">ITCHING </Semaphore>was received from a consumer in UNITED STATES.It was reported that the patient had <Semaphore x="1864833" class="Disease or Finding" value="Dry Eye Syndrome" score="1.00" ID="C34553"><Semaphore x="1864942" class="Disease or Finding" value="Dry Skin" score="1.00" ID="C74592">dry skin </Semaphore>around eyes </Semaphore>and <Semaphore x="1945418" class="AnatomicStructure" value="Forehead" score="1.00" ID="C89803">forehead</Semaphore>. The patient was prescribed an unspecified cream for <Semaphore x="1918283" class="AnatomicStructure" value="Face" score="1.00" ID="C13071">facial </Semaphore><Semaphore x="3210212" class="MedDRA LLT" value="Pruritus" score="1.00" ID="10037087">itching</Semaphore>. She was treated with <Semaphore x="1083207" class="Medicine" value="Preparation H" score="0.49" ID="257389">preparation H </Semaphore>for <Semaphore x="1534023" class="AnatomicStructure" value="Anus" score="1.00" ID="C43362">anal </Semaphore><Semaphore x="3210212" class="MedDRA LLT" value="Pruritus" score="1.00" ID="10037087">itching </Semaphore>and an oatmeal <Semaphore x="1675087" class="Disease or Finding" value="Cant" score="1.00" ID="C82117">base </Semaphore><Semaphore x="1610517" class="AnatomicStructure" value="Body" score="1.00" ID="C13041">body </Semaphore><Semaphore x="1734843" class="Procedure" value="Cell or Vector Cryopreservation" score="1.00" ID="C112963">wash </Semaphore>for <Semaphore x="1864942" class="Disease or Finding" value="Dry Skin" score="1.00" ID="C74592">dry skin</Semaphore>.Non serious follow up was received on 21-Jan 2013. New AE term added was <Semaphore x="2060292" class="Disease or Finding" value="Integumentary System Signs and Symptoms" score="0.58" ID="C5036">RASH </Semaphore><Semaphore x="1509811" class="Race" value="Andreafsky" score="1.00" ID="C44573">AND </Semaphore><Semaphore x="2060292" class="Disease or Finding" value="Integumentary System Signs and Symptoms" score="0.58" ID="C5036">ITCHING </Semaphore>ON THIGHS <Semaphore x="1509811" class="Race" value="Andreafsky" score="1.00" ID="C44573">AND </Semaphore>CALVES.</narrativeincludeclinical>
				<sendercomment>Non-serious event of dry skin is considered unexpected while rash pruritic, anal pruritus, anorectal discomfort and pruritus are considered expected for telaprevir. The concomitant drugs peg-interferon and ribavirin could be contributory factors for rash pruritic and pruritus while ribavirin also explains dry skin in this case.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>